
First-in-Class Therapies Designed to Reprogram the Immune System
Latest News
CBRE Arranges Expansion Lease for Cour Pharmaceuticals
November 18, 2021
November 19, 2021 / Press Releases
ABOUT COUR
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR’s lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions.
COUR Nanoparticle Platform: CNP

- Reprograms the immune system
- Induces tolerance to specific antigens
- Preserves all immune functionality
Inducing Immune Tolerance in Autoimmune & Allergic Diseases
Rapidly Advancing First-in-Class Therapies for Immune-Mediated Diseases
